Granules India Limited is a pharmaceutical manufacturing company based in Hyderabad, India. The company primarily focuses on the production of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulation intermediates, and Finished Dosage Formulations (FDF) for various therapeutic areas including gastro-intestinal, pain management, anti-infectives, and central nervous system drugs.

One of the key aspects that sets Granules India apart from its competitors is its focus on vertically integrated operations which include research & development, manufacturing of APIs and FDFs, and marketing & distribution. This vertical integration allows the company to have better control over quality and costs throughout the entire value chain.

The company has also made significant strides in technological innovation by leveraging processes such as continuous processing techniques for API production. Continuous processing offers advantages such as improved efficiency, reduced waste generation, and enhanced product consistency compared to traditional batch processing methods.

In terms of collaborations and partnerships, Granules India has established strategic alliances with several global pharmaceutical companies for contract manufacturing services as well as co-development and licensing agreements for generic products. These partnerships have enabled the company to expand its presence in international markets while enhancing its product portfolio with high-value generics.

With a strong focus on quality compliance and regulatory standards along with an expanding global footprint through exports to over 45 countries worldwide including regulated markets like US, Europe, Japan etc., Granules India continues to solidify its position as a leading player in the pharmaceutical industry.